Immutep Ltd

Immutep’s 2025 stock surge, driven by its Phase‑I IMP761 trial, highlights the highs and lows of biotech investing and the promise of new cancer immunotherapies.

Immutep Ltd, a biotechnology company based in Australia, is pioneering immunotherapy innovations and remains committed to advancing healthcare solutions despite market fluctuations.